Vyant Bio, Inc. (VYNT) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Cherry Hill, NJ, United States. The current CEO is Andrew D.C. LaFrence CPA.
VYNT has IPO date of 2021-04-01, 4 full-time employees, listed on the NASDAQ Capital Marke.
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.
